Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure

ClinicalTrials.gov ID: NCT02365818

Public ClinicalTrials.gov record NCT02365818. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open Label, Single Arm, Phase II, Multicenter Study of the Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients With Non-Muscle Invasive Bladder Carcinoma Who Have Failed BCG (Bacillus Calmette-Guerin) Therapy and Refused Cystectomy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To study the safety and efficacy of CG0070, an oncolytic virus expression GM-CSF in high grade non muscle invasive bladder cancer patients who failed BCG therapy and refused cystectomy.

Study identification

NCT ID: NCT02365818
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: CG Oncology, Inc.; Industry
Enrollment: 66 participants

Conditions and interventions

Conditions

Bladder Cancer

Interventions

CG0070 Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2, 2015 (Actual)
Primary completion: Aug 2018 (Actual)
Completion: Feb 2019 (Actual)
Last update posted: Apr 14, 2021

2015 – 2019

United States locations

U.S. sites: 17
U.S. states: 13
U.S. cities: 16

Facility	City	State	ZIP	Site status
Alaska Clinical Research Center	Anchorage	Alaska	99503	—
BCG Oncology	Phoenix	Arizona	85032	—
Arizona Institute of Urology	Tucson	Arizona	85704	—
Institute of Urologic Oncology at UCLA	Los Angeles	California	90095	—
UC Irvine Medical Center	Orange	California	92868	—
University of California, San Diego	San Diego	California	92093	—
UF Health Cancer Center	Gainesville	Florida	32610	—
University of Chicago	Chicago	Illinois	60637	—
Michigan Institute of Urology, P.C.	Troy	Michigan	48084	—
Adult Pediatric Urology and Urogynecology, PC	Omaha	Nebraska	68114	—
GU Research Network/ The Urology Center	Omaha	Nebraska	68130	—
Premier Urology Group, LLC.	Edison	New Jersey	08837	—
Premier Medical Group of the Hudson Valley	Poughkeepsie	New York	12061	—
Wake Forest University School of Medicine	Winston-Salem	North Carolina	27157	—
The Urology Group	Cincinnati	Ohio	45212	—
Vanderbilt University Medical Center, Dept. of Urologic Surgery	Nashville	Tennessee	37232	—
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02365818, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 14, 2021 · Synced Oct 19, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02365818 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →